St Jude Medical has stressed the importance of bringing together resources, people and technologies, following the launch of a study into atrial fibrillation (AF).
The Early Comprehensive Atrial Fibrillation Stroke Prevention Trial (EAST) will explore whether early, standardised intervention can aid in the prevention of adverse cardiovascular outcomes.
Jane Song, president of the St Jude Medical AF division, stressed the company's commitment to finding a cure for the disorder.
"We can help accelerate the achievement of this goal by investing in clinical trials such as EAST, which address some of the most important questions about AF within the scientific community," she said.
The firm hopes to enrol more than 3,000 patients across Europe in the study, with the first one having signed up this week.
Last month, St Jude Medical announced its second-quarter financial results, which indicated that the company saw its sales rise ten percent compared with the same period of 2010.See all the latest jobs in Medical Devices